{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lin C"],"funding":["National Science and Technology Council","Taipei Medical University"],"pagination":["41"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12809945"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(1)"],"pubmed_abstract":["Aortic dissection (AD) is a life‑threatening vascular disorder with high mortality and no effective pharmacological treatment. Addressing its multicellular and dynamic pathology requires strategies that precisely modulate inflammatory and degenerative processes, yet existing targeted delivery approaches lack the spatiotemporal and cellular precision required. Here, we establish Galectin‑3 (Gal‑3) as a therapeutic delivery target for cardiovascular nanomedicine and introduce a modular, pathology‑tailored nanoplatform synergizing nitric oxide (NO) therapy with multi‑pathway intervention. Gal‑3 is persistently expressed on inflamed endothelial cells, macrophages, and smooth muscle cells during AD progression, providing a tractable target for lesion‑specific engagement. The nanoparticles, crea"],"journal":["Journal of nanobiotechnology"],"pubmed_title":["Pathology-tailored nanotherapy via Galectin-3-targeted and triple-responsive nanoparticles enables multimodal therapy against aortic dissection."],"pmcid":["PMC12809945"],"funding_grant_id":["112-2314-B-038-122-MY3, 113-2314-B-038-066-MY3","111-2314-B-038-093-MY3, 113-2314-B-038-009, 114-2314-B-038-159","DP2-TMU-114-O-01, 113TMU-WFH-09"],"pubmed_authors":["Cheng CH","Shih CM","Lin C","Wu ATH","Tsai ML","Mi FL","Shih CC","Lu HY","Chao HY","Cheng TM","Hsiao CY"],"additional_accession":[]},"is_claimable":false,"name":"Pathology-tailored nanotherapy via Galectin-3-targeted and triple-responsive nanoparticles enables multimodal therapy against aortic dissection.","description":"Aortic dissection (AD) is a life‑threatening vascular disorder with high mortality and no effective pharmacological treatment. Addressing its multicellular and dynamic pathology requires strategies that precisely modulate inflammatory and degenerative processes, yet existing targeted delivery approaches lack the spatiotemporal and cellular precision required. Here, we establish Galectin‑3 (Gal‑3) as a therapeutic delivery target for cardiovascular nanomedicine and introduce a modular, pathology‑tailored nanoplatform synergizing nitric oxide (NO) therapy with multi‑pathway intervention. Gal‑3 is persistently expressed on inflamed endothelial cells, macrophages, and smooth muscle cells during AD progression, providing a tractable target for lesion‑specific engagement. The nanoparticles, crea","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-15T11:17:38.001Z","creation":"2026-07-04T03:12:17.483Z"},"accession":"S-EPMC12809945","cross_references":{"pubmed":["41530721"],"doi":["10.1186/s12951-025-04012-7"]}}